Track topics on Twitter Track topics that are important to you
This is a non-interventional, observational study in which HUMIRA (adalimumab) is prescribed in the usual manner in accordance with the terms of the local marketing authorisation with regards to dose, population and indication. No data currently exist that characterise patient types and adalimumab administration within the Russian population. Further, it is important to characterise the compliance, acceptability of patient self-injection, tolerability and safety profile of this newly introduced therapy option with the routine clinical care.
Primary objective The primary objective of this post-marketing observational study is to obtain data on the characteristics (patient age/gender; disease type, severity and duration; disease specific treatment history, including DMARDs/BDMARDs; current concomitant medications; other relevant medical history, including TB (prior diagnosis/effectiveness of treatment; screening and prophylaxis history) of patients prescribed HUMIRA (adalimumab) for RA/AS/PsA as part of routine clinical care.
- disease-modifying antirheumatic drugs (DMARDs)
- biological disease-modifying antirheumatic drugs (bDMARDs)
- rheumatoid arthritis (RA)
- ankylosing spondylitis (AS)
- psoriatic arthritis (PsA)
- tuberculosis (TB)
- Patient acceptability of self-injection and compliance with therapy
- Clinical tolerability and safety
Time Perspective: Prospective
Site Reference ID/Investigator# 6002
Published on BioPortfolio: 2014-07-23T21:08:07-0400
Primary aim: examine a possible connection between cigarette smoking, disease activity and perceived pain in patients with rheumatoid arthritis. Secondary aim: Evaluate cardiovascular ris...
The purpose of this study is to compare the incidence rates of infection, malignancy and death among patients with rheumatoid arthritis who are treated with abatacept and those who are tre...
Objective: To evaluate what factors contribute to activity limitations in subjects with rheumatoid arthritis considering the International Classification of Functioning, Disability and Hea...
Patients with rheumatoid arthritis are at increased risk of having cardiovascular deaths. Our study is aimed at looking at the effects of proven cholesterol lowering treatment drug called ...
This study will look at whether this new drug is effective in the treatment of rheumatoid arthritis, and at whether it is safe and well-tolerated by patients with the disease.
Rheumatoid arthritis (RA) as an inflammatory autoimmune disease affects the synovial joints as well as other organs and tissues. Since aberrant expression of MIC molecules has been observed in RA pati...
Rheumatoid arthritis is associated with an increased cardiovascular risk, secondary to endothelial dysfunction. There is accumulating evidence that methotrexate reduces cardiovascular risk in rheumato...
Chronic inflammation of rheumatoid arthritis (RA) is associated with disturbances in muscle and bone metabolism.
To explore the role of TNF-α in the peripheral blood of patients with rheumatoid arthritis (RA) and its underlying mechanism.
Interferon alpha-induced arthritis and activation of the type 1 interferon pathway during rheumatoid arthritis (RA) has been well documented but the underlying mechanism remains unclear. This study ad...
Arthritis in children, with onset before 16 years of age. The terms juvenile rheumatoid arthritis (JRA) and juvenile idiopathic arthritis (JIA) refer to classification systems for chronic arthritis in children. Only one subtype of juvenile arthritis (polyarticular-onset, rheumatoid factor-positive) clinically resembles adult rheumatoid arthritis and is considered its childhood equivalent.
Rheumatoid arthritis of children occurring in three major subtypes defined by the symptoms present during the first six months following onset: systemic-onset (Still's Disease, Juvenile-Onset), polyarticular-onset, and pauciarticular-onset. Adult-onset cases of Still's disease (STILL'S DISEASE, ADULT-ONSET) are also known. Only one subtype of juvenile rheumatoid arthritis (polyarticular-onset, rheumatoid factor-positive) clinically resembles adult rheumatoid arthritis and is considered its childhood equivalent.
A variable mixture of the mono- and disodium salts of gold thiomalic acid used mainly for its anti-inflammatory action in the treatment of rheumatoid arthritis. It is most effective in active progressive rheumatoid arthritis and of little or no value in the presence of extensive deformities or in the treatment of other forms of arthritis.
Systemic-onset rheumatoid arthritis in adults. It differs from classical rheumatoid arthritis in that it is more often marked by acute febrile onset, and generalized lymphadenopathy and hepatosplenomegaly are more prominent.
Antibodies found in adult RHEUMATOID ARTHRITIS patients that are directed against GAMMA-CHAIN IMMUNOGLOBULINS.